With the completion of the entire human genome sequence and remarkable advances in genotyping technologies, there has been an increased interest in the application of genetics and genomics in biomedical research over the last decade. Large-scale population-based genetic association studies have now become routine and their application to several multifactorial diseases such as cardiovascular disorders has led to the identification of a number of novel susceptibility genes. However, to be able to interpret results from such studies, clinicians need to have a basic understanding of unique concepts and issues related to this fast-moving area of research. In this primer, we provide a broad overview of design, analysis, and methodological issues with a focus on population-based study design.
Introduction
Recent technological and methodological advances in genomics have led to considerable improvements in our understanding of cardiovascular disease (CVD) genetics. Candidate gene association studies examine only a few variants in a narrow genetic region typically focussed on a specific gene. The advent of reliable and affordable techniques to type genetic variants in DNA samples (i.e. genotyping) coupled with a comprehensive cartography of common genetic variants (i.e. the HapMap project 1 ) has provided the basis for genomewide association studies (GWASs). Genome-wide association studies involve genotyping from 100 000 up to 5 000 000 common genetic variants throughout the genome-generally singlenucleotide polymorphisms or SNPs-in thousands of individuals in order to agnostically search for genetic associations. Genome-wide association studies have proven very successful at identifying genetic loci associated with traits of interest. Indeed, over 1100 genetic associations have now been described with a variety of phenotypes (www.genome.gov/gwastudies/), including 46 associations with myocardial infarction (MI). 2 Some of the criticisms of GWAS include: (i) the initial successful work with macular degeneration was supported by a large clinical effect; on the other hand, most work with CVD has required large sample sizes due to the relatively smaller effects; (ii) GWASs are not suitable to detect rare variants; for such variants sequencing approaches are needed; and (iii) the relative cost of GWASs can be high, but given the large number of variants that can be investigated simultaneously and the constant decrease in cost, this issue may not be serious. The distinct nature of genetic studies dictates the need for study designs and analysis schemes adapted to genetic data. Indeed, some statistical challenges are unique to genetic epidemiology, most notably extensive multiple hypothesis testing and population stratification. In this review, key concepts in statistical genetics will be explained. The goal is to discuss commonly encountered issues in the interpretation of genetic studies rather than provide an in-depth overview of the rapidly expanding field of statistical genetics. Specifically, we will outline the most common study designs, procedures for quality control of genotypes and analysis strategies. We will further discuss population stratification and multiple hypothesis testing considerations.
Design
There are two broad classifications of study designs that are commonly used in genetic studies, namely family-based and populationbased study designs. 3 -6 Each study design has its pros and cons. In this paper, we will only discuss population-based study designs, as they are the most common ones. The case -control study design is widely used to investigate the association between exposure and outcome in observational epidemiology in general, and genetic epidemiology in particular. The case -control design is simple to undertake and the analytical approaches to analyse data arising from this design are well established. In such designs, cases and controls are ascertained for any disease or trait and interest lies in comparing the risks or probabilities of exposure in the two groups. If the probabilities of exposure differ markedly, this would suggest that the exposure variable is associated with the case-control status. A classic example of case -control study design in observational epidemiology is the association between smoking and the risk of developing lung cancer. 7 In this example, smoking is the exposure variable and lung cancer is the outcome, i.e. 'case', of interest. This example highlights the importance of case-control design for situations where exposure cannot be imposed because of ethical or other considerations, as one would not expose subjects to effects of smoking and follow them to ascertain the outcome prospectively.
In genetic epidemiology involving a case-control study design, the exposure would typically be carrier of a particular genetic variant at locus along the genome (see more details below) and the outcome might be a disease such as being a 'case' of type 2 diabetes vs. controls. Selecting appropriate controls is not trivial and must be done carefully to minimize selection bias. 8 Other types of biases that are often attributed to the lack of accuracy of environment or lifestyle-driven exposure variables, such as recall bias, are not a concern in the context of genetics in which the exposure is genotype-driven. 9 The genotype of an individual is determined using laboratory techniques, and the only issue that may complicate the exposure in this case is the possibility of poor DNA quality and thus, the potential for genotyping error as discussed below.
Quality control considerations
After genotype, data have been generated in the laboratory, an important step is to perform data cleaning and quality control. This is usually done using a combination of procedures. this offers a good balance between a low P value due to chance vs. the other reasons mentioned given the number of tests performed in a GWAS. Other quality control procedures involve filtering SNPs based on differences in call rates between cases and controls, examining the pair-wise genetic relatedness between samples in order to detect cryptic relatedness or frank duplication of samples, and comparing the genetic sex of individuals to the self-reported sex to identify sample mix-ups. Increased heterozygosity can also indicate poor DNA quality and can be used to exclude samples. It is always important to indicate minor allele frequencies of genotyping results.
Scale of outcome and statistical analysis
The nature of the outcome variable under investigation plays a key role in both the design and the analysis phase of a research study.
Types of outcomes include binary where there are only two possibilities (e.g. presence or absence of a disease such as MI vs. controls), continuous for which a measurement is obtained on a spectrum of values (e.g. cholesterol level, blood pressure), and a time-to event outcome (e.g. time to death after a cardiac event). Other types of outcomes including count data (e.g. number of asthma attacks over a specified time interval), ordinal data (e.g. disease severity categorized as 'mild', moderate' or 'severe') can also arise, but are not common in cardiovascular research. Each outcome type can result in a different sample size estimate for the study and the method of making formal statistical inference such as constructing confidence intervals for parameters or testing hypotheses will also vary. Each outcome type does also demand for different statistical parameters as well as different ways of graphical illustration.
Data structure, analysis and the impact of assumed genetic model
In this section, we will briefly discuss how data are typically organized and analysed for testing the association between a single SNP and case -control status. As an example, suppose we are interested in testing the association between a given SNP and the risk of MI. 
Different genetic models
In Table 1 , if G is the variant of interest (a high-risk allele), a dominant genetic model leads to comparing CC genotypes with CG + GG genotypes. Likewise, one may compare CC + CG with GG genotypes if a recessive genetic model is assumed. Under the assumption of either a dominant or recessive model, the data in Table 1 will reduce to a simple 2 by 2 table and a chi-square test with one degree of freedom can be used to determine statistical significance. Once again, the exact methods or correction factors would need to be used if data are sparse.
Another alternative is to test for association between the number of copies of the risk variant and the outcome assuming an additive model. This is the most commonly assumed genetic model, in particular in GWASs and the statistical significance is assessed based on the Cochrane-Armitage test for trend. Finally, although not very common, one could also test for a difference in allele frequency between cases and controls (this is called the multiplicative model). Table 2 shows a 2 by 2 table obtained from counting alleles based on the data from Table 1 . Once again, the allelic association can be tested using a simple chi-square test with one degree of freedom. For this example, analysis of the data in Table 2 using a chi-square test results in a highly statistically significant association (P value ¼ 1.1 × 10
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).
Adjusting for covariates
The chi-square based tests do not allow covariates into the analysis. Such analyses are called univariate or unadjusted analyses.
Sometimes the analyst might want to control for important covariates. In that case, an extension of the chi-square test is a logistic regression model where a binary outcome is related to a number of risk factors along with the genetic marker of interest. Like the unadjusted case, different genetic models can be assumed leading to different ways of handling genotypes. The most common approach in a logistic model is to code SNPs based on the number of copies of the minor allele and estimate only one parameter per SNP. Within the regression framework, one can test for association between genetic markers and phenotype adjusting for important covariates such as gender, age, and ethnicity.
Continuous or quantitative phenotypes
The case-control design discussed above is an example of a dichotomous or qualitative outcome. Both the chi-square test and the logistic regression model described above are only useful to dealing with binary or categorical outcomes. In practice, however, one might also be interested in analysing quantitative or continuous variables. Genetic associations involving continuous phenotypes, such as blood pressure, cholesterol, and height, can be performed using a linear regression model. The linear regression model is readily available in many statistical software packages. However, the user must be aware of some important assumptions behind this modelling framework. For example, the phenotype is assumed to have a normal distribution, which may be violated in some situations. In the study of lipid profiles for example, triglyceride is often skewed and thus violates one of the fundamental assumptions required by the linear regression model. Gross violation can lead to erroneous conclusions and inferences. Outliers can also result in poor performance of these methods. Appropriate transformation (for example, logarithmic transformation) or robust methods that are less sensitive to outliers should be used if assumptions are violated. Similar to the general contingency table analysis in the unadjusted case discussed earlier for the three genotype classes, one could use the analysis of variance (ANOVA) method to compare the average of the quantitative trait across the three groups. For example, it might be of interest to test if average systolic blood pressure varies across genotype classes.
If the outcome has both a binary and continuous component, such as a time-to-event outcome, appropriate regression approaches such as the Cox regression model can be used. All the approaches described so far can be used with candidate gene studies as well as with large-scale GWASs. In the GWAS setting, the statistical tests described above will have to be carried out, one at a time, for all SNPs that passed standard quality control filters. Although testing each variant for association with an outcome is straightforward, there are some methodological issues that can complicate the interpretation of findings from such studies. We describe selected methodological issues below.
Methodological issues Population stratification
Population stratification is a source of confounding in genetic epidemiology studies. 10 One approach to minimizing the confounding effects of population stratification is to match participants based on the geographical region and by markers of ethnic origin-so-called structured association. 11 Stratifying the study sample by ethnic groups allows for fair comparisons among homogenous groups; however, depending on the amount of stratification, too many groups will decrease the power to detect an effect within each stratum. Genetic principal components are also widely used to minimize confounding by stratification. This method corrects for spurious associations in traits that differ among populations and have different allelic frequencies for the genotype of interest. Most differences in allelic frequencies are thought to have occurred because of genetic drift and may not represent functional variants. 13 Thus, the principal component analysis technique is used to detect and correct for the population heterogeneity to minimize false-positive associations. 14 Variance component methods have also been recently developed to adjust for population stratification and are rapidly gaining popularity. 15 Importantly, randomized clinical trials are immune to this bias since equal numbers of individuals of each population strata will be randomized to the drug of interest or the placebo group. Pharmacogenetic analysis of a randomized trial should thus try to preserve randomization status when searching for gene by intervention interactions.
Multiple testing and power
One major challenge that can complicate interpretation is the issue of multiple testing. Association analysis for GWAS and related large-scale experiments require conducting a very large number of statistical tests. Unless appropriate corrections are applied, such multiple testing problems could result in inflated type I error, i.e. declaring association when it does not exist. For example, if the typical 5% type I error is assumed and 1000 statistically independent tests are carried out, one can expect 1000 × 0.05 ¼ 50 false positives. For independent tests, a Bonferroni correction can be used. Using this method of multiple testing correction, the nominal significance level (e.g. 0.05) is divided by the number of tests. For example, if one tests 1 million hypotheses, the Bonferroni correction suggests that associations should be deemed to be statistically significant if P values are ,0.05/1 million ¼ 5 × 10
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. If the tests are correlated, which will, for example, be the case with testing multiple SNPs, the Bonferroni correction will be conservative. SNPs are expected to be correlated because of linkage disequilibrium (LD). In the analysis of GWAS data, it has been estimated that testing for all common variants in European Caucasians is equivalent to 1 million statistical test 16 and the genome-wide significance level is thus typically set at 5 × 10
28 . There are other less conservative multiple testing correction methods that have been proposed in recent years. One such method, the false-discovery rate (FDR) approach has become a popular approach in dealing with multiple testing problems in large-scale genomic studies, in particular studies of microarray gene expression. In simple terminology, the FDR is defined as the expected rate of erroneous rejection of hypotheses among the total rejected hypotheses. Procedures that control FDR impose a less stringent control over false discovery compared with other multiple testing corrections such as the Bonferroni method, leading to an increase in power at the cost of increasing type I error. Permutation tests can also be used to determine empirical levels of significance. Permutation tests can be used with complex data structures but they also have some limitations because of the inherent computational burden with these procedures.
Multiple testing is about type I error. Another potential problem is type II error, which relates to a lack of power to detect true association. It is well known that for most complex disorders and traits effect sizes are small to moderate, which makes it extremely difficult to detect them. A large sample size will be needed to detect such small effects and large-scale multi-team collaborative studies with participants recruited from several populations or meta-analyses of individual studies are necessary. Careful phenotyping is crucial when looking for subtle effects. If researchers include cases that are fairly heterogeneous (e.g. various cardiomyopathies grouped together as heart failure), then it will be very challenging to detect true genetic relationships.
Meta-analyses of GWASs have been successful in identifying novel genetic variants for complex diseases not previously identified by single studies. For example, a recent large-scale study included 63 746 coronary artery disease cases and 130 681 controls identifying susceptibility loci reaching genome-wide significance. 2 Although this is perhaps an extreme case, clinicians however should be aware that a large sample size is a critical factor for success in gene mapping studies involving complex phenotypes. Issues related to sample size and statistical power can also be viewed in light of the objective of the research, namely confirmatory vs. exploratory. In hypothesis-driven studies such as randomized clinical trials, for example, the investigator will typically estimate the sample size to achieve a prespecified level of power for a primary outcome, but often there will be several secondary outcomes that will be analysed and considered exploratory in nature.
Discussion
Genome-wide association studies have already identified thousands of genetic associations between SNPs and common disease. 17 These discoveries have led to novel insights into the genetic basis of common diseases such as CVD. Furthermore, genes identified by GWASs are enriched in high-value biological targets such as clinically proven drug targets and druggable genes, as demonstrated by the observation that GWAS hits identified numerous marketed drug targets for type 2 diabetes (n ¼ 6), hyperlipidaemia (n ¼ 2), multiple sclerosis (n ¼ 5) and psoriasis (n ¼ 4). 18 While robust findings can be expected from well-executed and methodologically sound studies, failure to appreciate statistical challenges specific to genetic association studies can lead to spurious results. This is particularly true of adjustment for multiple hypothesis testing, population stratification, and the need for adequately powered studies. Indeed, before these phenomena were recognized, early genetic association studies have been plagued by falsely positive results. 19 Fortunately, standards have greatly improved since such robust findings are to be expected from contemporary experiments. The nature of the research question, namely confirmatory vs. exploratory, will also have bearing in issues related to multiple testing and power analysis. Furthermore, it is important to distinguish a purely statistical association from a causal (genetic or environmental) effect. With rapid advances in laboratory and statistical methods, the pace of discoveries in cardiovascular genetics will likely accelerate in the coming years, paving the way for identification of novel pathophysiologic pathways and personalized medicine.
Glossary Allele
An allele is one of two or more versions of a gene. An individual inherits two alleles for each gene, one from each parent. If the two alleles are the same, the individual is homozygous for that gene. If the alleles are different, the individual is heterozygous. Though the term 'llele' was originally used to describe variations among genes, it now also refers to variations among non-coding DNA sequences (National Human Genome Research Institute).
Dominant
One mutated copy of the gene in each cell is sufficient for a person to be affected by an autosomal-dominant disorder. Each affected person usually has one affected parent. Autosomal-dominant disorders tend to occur in every generation of an affected family (National Library of Medicine).
Genome-wide association study
An analysis comparing the allele frequencies of all available (or a whole-genome representative set of) polymorphic markers in unrelated patients with a specific symptom or disease condition, and those of healthy controls to identify markers associated with a specific disease or condition (National Library of Medicine).
Genotype
The two alleles inherited for a particular gene. The genotype is expressed when the information encoded in the genes' DNA is used to make protein and RNA molecules. The expression of the genotype contributes to the individual's observable traits, called the phenotype (National Human Genome Research Institute).
Hardy -Weinberg Law
The concept that both gene frequencies and genotype frequencies will remain constant from generation to generation in an infinitely large, interbreeding population in which mating is at random and there is no selection, migration or mutation. (National Institute of Health).
Linkage disequilibrium
The nonrandom association of alleles between two or more loci such that certain combinations of alleles are more likely to occur together than would be predicted by allele frequencies.
Recessive
Two mutated copies of the gene are present in each cell when a person has an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Autosomal recessive disorders are typically not seen in every generation of an affected family. (National Library of Medicine).
Single-nucleotide polymorphism
A single-nucleotide variation in a genetic sequence occurs at appreciable frequency in the population (National Library of Medicine).
